<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83874">
  <stage>Registered</stage>
  <submitdate>1/05/2009</submitdate>
  <approvaldate>21/05/2009</approvaldate>
  <actrnumber>ACTRN12609000323224</actrnumber>
  <trial_identification>
    <studytitle>Ultrasound scanning with contrast enhancement to assess disease activity in Crohn's disease</studytitle>
    <scientifictitle>Contrast-enhanced ultrasound assessment of Crohn's disease activity</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Crohn's disease</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Crohn's disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Observational study - participants will receive up to two bolus intravenous injections of ultrasound contrast (perflutren lipid microsphere, each bolus approximately 0.75ml of contrast agent diluted to 5ml with normal saline) on each of the two visits. Contrast enhancement of the bowel wall will be observed for approximately 10 minutes post injection.</interventions>
    <comparator>No concurrent controls. Patient will act as their own internal controls.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Comparison of quantitative parameters derived from time-intensity curve of contrast enhancement of bowel wall with clinical and endoscopic parameters of disease activity</outcome>
      <timepoint>Outcomes will be measured once at enrolment and once on the second visit approximately 4-6 weeks post enrolment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Comparison of bowel wall thickness with clinical and endoscopic parameters of disease activity</outcome>
      <timepoint>Outcomes will be measured once at enrolment and once on the second visit approximately 4-6 weeks post enrolment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with Crohns disease who are experiencing an exacerbation (Crohns disease activity index, CDAI &gt;150) and who require a colonoscopy or flexible sigmoidoscopy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnant and lactating women, patients with abdominal surgery during the past 6 months, known right-to-left intracardiac shunts, unstable cardiac disease, pulmonary hypertension, severe chronic obstructive pulmonary disease, pulmonary vasculitis and hypersensitivity to ultrasound contrast agents.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/03/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Perth Hospital</primarysponsorname>
    <primarysponsoraddress>Wellington St,
Perth WA 6000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Lantheus Medical Imaging</fundingname>
      <fundingaddress>Bldg. 200-2
331 Treble Cove Rd,
N. Billerica, MA 01862</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to determine whether measurements obtained from an ultrasound scan of the bowel with the use of a contrast agent provides useful information on the disease activity of patients with Crohn's disease.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Wellington St,
Perth WA 6000</ethicaddress>
      <ethicapprovaldate>17/12/2008</ethicapprovaldate>
      <hrec>EC2008/199</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof Richard Mendelson</name>
      <address>Department of Diagnostic and Interventional Radiology
Royal Perth Hospital
Wellington St,
Perth WA 6000</address>
      <phone>+61 8 9224 2129</phone>
      <fax />
      <email>richard.mendelson@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Daniel Wong</name>
      <address>Department of Diagnostic and Interventional Radiology
Royal Perth Hospital
Wellington St,
Perth WA 6000</address>
      <phone>+61 8 9224 2721</phone>
      <fax />
      <email>daniel.wong@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Daniel Wong</name>
      <address>Department of Diagnostic and Interventional Radiology
Royal Perth Hospital
Wellington St,
Perth WA 6000</address>
      <phone>+61 8 9224 2721</phone>
      <fax />
      <email>daniel.wong@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>